BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
9.70
-0.12 (-1.22%)
At close: Aug 31, 2026, 4:00 PM EDT
9.55
-0.15 (-1.55%)
After-hours: Aug 31, 2026, 7:57 PM EDT
BioCryst Pharmaceuticals Employees
BioCryst Pharmaceuticals had 435 employees as of December 31, 2025. The number of employees decreased by 145 or -25.00% compared to the previous year.
Employees
435
Change (1Y)
-145
Growth (1Y)
-25.00%
Revenue / Employee
$2,162,329
Profits / Employee
-$884,306
Market Cap
2.48B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 435 | -145 | -25.00% |
| Dec 31, 2024 | 580 | 44 | 8.21% |
| Dec 31, 2023 | 536 | 5 | 0.94% |
| Dec 31, 2022 | 531 | 173 | 48.32% |
| Dec 31, 2021 | 358 | 112 | 45.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| HUTCHMED (China) | 1,790 |
| Alvotech | 1,279 |
| ANI Pharmaceuticals | 970 |
| Prestige Consumer Healthcare | 890 |
| Supernus Pharmaceuticals | 778 |
BCRX News
- 3 days ago - BioCryst is profitable. Now it wants to buy more rare disease drugs - CNBC
- 6 days ago - BioCryst announces Japan MHLW marketing approval for Orladeyo - TheFly
- 6 days ago - BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan - GlobeNewsWire
- 25 days ago - BioCryst price target lowered to $20 from $21 at Wedbush - TheFly
- 25 days ago - BioCryst price target lowered to $13 from $14 at RBC Capital - TheFly
- 26 days ago - BioCryst Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 26 days ago - BioCryst Pharmaceuticals Earnings release: Q2 2026 - Filings
- 26 days ago - BioCryst Pharmaceuticals Slides: Q2 2026 - Filings